Sygnis Pharma

SYGNIS Pharma AG, a specialty pharmaceutical company, engages in the research, development, and marketing of drugs for the treatment of.

Launch date

1997

Employees

Company register number HRB 335706 (Mannheim)

Heidelberg Baden-Württemberg (HQ)

http://sygnis.de

https://twitter.com/sygnisag http://www.facebook.com/pages/Sygnis-AG/222842631207751

Revenues, earnings & profits over time

EUR	2015	2016	2017	2018	2019	2020
Revenues	<1m	2.0m	8.0m	<1m	<1m	<1m
% growth	-	229 %	300 %	(98 %)	27 %	(66 %)
EBITDA	(3.5m)	-	-	-	(2.0m)	60.0m
% EBITDA margin	(579 %)	-	-	-	(995 %)	86957 %
Profit	(4.0m)	-	-	-	-	-
% profit margin	(661 %)	-	-	-	-	-
EV / revenue	64.7x	-	-	-	-	-
EV / EBITDA	-11.2x	-	-	-	-	-
R&D budget	1.9m	-	-	-	-	-
R&D % of revenue	309 %	-	-	-	-	-

Source: Dealroom estimates

Date	Investors	Amount	Round
Feb 2012	N/A	N/A	IPO
Dec 2012	N/A	N/A	IPO
Total Funding		-

ACQUISITION by Sygnis Pharma Jun 2008

C.B.S. Scientific Company

ACQUISITION by Sygnis Pharma Dec 2016

Innova Biosciences

ACQUISITION by Sygnis Pharma Jun 2017